Cubist Pharmaceuticals Inc. said that the Food and Drug Administration has approved expanded use for Entereg, a drug used after gastrointestinal surgery.
Entereg is designed to accelerate healing following certain surgeries, Lexington-based Cubist said. Entereg was approved in the United States in 2008.
“Delayed GI (gastrointestinal) recovery is one of the most common causes of prolonged hospital stays in patients undergoing major abdominopelvic surgery,” Cubist chief scientific officer Steven Gilman said in a statement. “We are pleased that doctors will have the option to help speed GI recovery for appropriate patients who have undergone surgeries that included a bowel resection.”